Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401

Vaccination with dendritic cell (DC)/multiple myeloma (MM) fusions has been shown to induce the expansion of circulating multiple myeloma-reactive lymphocytes and consolidation of clinical response following autologous hematopoietic cell transplant (auto-HCT). In this randomized phase II trial (NCT0...

Full description

Bibliographic Details

Published in:	Clinical cancer research Vol. 29; no. 23; p. 4784
Main Authors:	Chung, David J, Shah, Nina, Wu, Juan, Logan, Brent, Bisharat, Lina, Callander, Natalie, Cheloni, Giulia, Anderson, Kenneth, Chodon, Thinle, Dhakal, Binod, Devine, Steve, Somaiya Dutt, Poorvi, Efebera, Yvonne, Geller, Nancy, Ghiasuddin, Haider, Hematti, Peiman, Holmberg, Leona, Howard, Alan, Johnson, Bryon, Karagkouni, Dimitra, Lazarus, Hillard M, Malek, Ehsan, McCarthy, Philip, McKenna, David, Mendizabal, Adam, Nooka, Ajay, Munshi, Nikhil, O'Donnell, Lynn, Rapoport, Aaron P, Reese, Jane, Rosenblatt, Jacalyn, Soiffer, Robert, Stroopinsky, Dina, Uhl, Lynne, Vlachos, Ioannis S, Waller, Edmund K, Young, James W, Pasquini, Marcelo C, Avigan, David
Format:	Journal Article
Language:	English
Published:	United States 01.12.2023
Subjects:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Dendritic Cells Dexamethasone - therapeutic use Granulocyte-Macrophage Colony-Stimulating Factor - genetics Hematopoietic Stem Cell Transplantation Humans Lenalidomide - therapeutic use Multiple Myeloma - drug therapy Transplantation, Autologous
ISSN:	1557-3265, 1557-3265
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!